NASDAQ · MGTX
Healthcare · Biotechnology
$10.60
Down-$0.32 (-2.93%)
Updated Oct 7, 2026, 9:48 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MGTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MGTX closed at $10.60 after 21 trading sessions, down 21.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $10.93 | $10.95 | $10.525 | $10.60 | 944.44K |
| Oct 5, 2026 | $10.77 | $11.03 | $10.59 | $10.92 | 941.65K |
| Oct 2, 2026 | $10.75 | $11.00 | $10.655 | $10.79 | 820.04K |
| Oct 1, 2026 | $11.36 | $11.36 | $10.535 | $10.66 | 1.07M |
| Sep 30, 2026 | $11.19 | $11.60 | $10.97 | $11.00 | 1.42M |
| Sep 29, 2026 | $11.02 | $11.17 | $10.87 | $11.13 | 875.93K |
| Sep 28, 2026 | $10.79 | $11.27 | $10.59 | $11.11 | 930.01K |
| Sep 25, 2026 | $10.90 | $11.28 | $10.68 | $10.91 | 1.56M |
| Sep 24, 2026 | $11.42 | $11.555 | $11.00 | $11.05 | 1.61M |
| Sep 23, 2026 | $12.26 | $12.50 | $11.46 | $11.75 | 1.42M |
| Sep 22, 2026 | $13.16 | $13.24 | $12.18 | $12.35 | 1.44M |
| Sep 21, 2026 | $13.47 | $13.47 | $12.80 | $13.08 | 1.29M |
| Sep 18, 2026 | $12.92 | $13.34 | $12.92 | $13.25 | 941.21K |
| Sep 17, 2026 | $13.21 | $13.34 | $12.9125 | $13.05 | 953.04K |
| Sep 16, 2026 | $12.79 | $12.95 | $12.63 | $12.76 | 917.36K |
| Sep 15, 2026 | $12.88 | $12.885 | $12.50 | $12.76 | 1.03M |
| Sep 14, 2026 | $12.81 | $13.22 | $12.76 | $12.88 | 492.32K |
| Sep 11, 2026 | $13.04 | $13.14 | $12.75 | $12.79 | 459.55K |
| Sep 10, 2026 | $13.02 | $13.16 | $12.645 | $12.85 | 716.51K |
| Sep 9, 2026 | $13.40 | $13.76 | $13.245 | $13.26 | 534.37K |
| Sep 8, 2026 | $13.539 | $13.72 | $13.2174 | $13.53 | 611.45K |
The latest Smart Investors Daily articles mentioning MGTX.
Company
Market Activity
Research & News
MGTX research
Company profile and research snapshot.
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Jul 8, 2026 | RBC Capital | Outperform | — |
| Jul 8, 2026 | HC Wainwright & Co. | Buy | — |
| May 15, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 24, 2026
Goldman Sachs analyst Andrea Newkirk initiates coverage on MeiraGTx Holdings (NASDAQ:MGTX) with a Neutral rating and announces Price Target of $16.
Yahoo · Sep 23, 2026
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most rec
Yahoo · Aug 26, 2026
Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a multicenter Phase Ib/II multi-dose, open-label clinical trial evaluating the safety, tolerability, and efficacy of GV101 in patients with moderate to severe chronic Graft versus Host Disease (cGvHD). The data, published in Signal Transduction and Targeted Therapy, a Springer Nature Portfolio journal, provide efficacy and findings from the 60 enrolled pat
ChartMill · Aug 21, 2026
MeiraGTx: Minervini trend template and high-growth screen confirm uptrend, high relative strength, explosive growth. Low setup rating means wait.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MGTX.
